ESC Heart Failure

Papers
(The H4-Index of ESC Heart Failure is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Heart failure after myocardial infarction: incidence and predictors237
Detection of viral SARS‐CoV‐2 genomes and histopathological changes in endomyocardial biopsies178
Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID‐19): autopsy reveals a ferroptosis signature92
Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives83
Machine learning vs. conventional statistical models for predicting heart failure readmission and mortality83
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis75
Left bundle branch area pacing delivery of cardiac resynchronization therapy and comparison with biventricular pacing74
Echocardiographic abnormalities and predictors of mortality in hospitalized COVID‐19 patients: the ECHOVID‐19 study73
Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock68
Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes66
Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic66
Sarcopenia in heart failure: a systematic review and meta‐analysis66
Anaemia, iron deficiency and heart failure in 2020: facts and numbers61
Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus59
Cardiogenic shock teams and centres: a contemporary review of multidisciplinary care for cardiogenic shock50
Familial screening in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies50
Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)49
The detrimental effect of COVID‐19 nationwide quarantine on accelerometer‐assessed physical activity of heart failure patients49
Pulmonary artery catheter use in acute myocardial infarction‐cardiogenic shock48
Heart failure in the last year: progress and perspective48
Frailty and the risk of all‐cause mortality and hospitalization in chronic heart failure: a meta‐analysis47
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data47
Iron deficiency in heart failure47
Motivational interviewing to improve self‐care in heart failure patients (MOTIVATE‐HF): a randomized controlled trial47
Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player45
Hospital readmissions of patients with heart failure from real world: timing and associated risk factors44
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials44
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial43
Effect of sacubitril/valsartan on renal function: a systematic review and meta‐analysis of randomized controlled trials42
Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure41
Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction40
Delayed acute myocarditis and COVID‐19‐related multisystem inflammatory syndrome38
Cardiac performance in patients hospitalized with COVID‐19: a 6 month follow‐up study38
‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor37
How to consider target heart rate in patients with systolic heart failure35
Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors35
0.049412965774536